Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$8.37
$8.37
$2.66
$8.55
$401.26M0.522.97 million shsN/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
$3.98
+5.6%
$4.01
$3.32
$7.32
$144.75M0.795,484 shs2,011 shs
PetIQ, Inc. stock logo
PETQ
PetIQ
$17.04
+1.2%
$17.10
$11.26
$22.98
$501.49M1.68193,283 shs166,660 shs
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
$8.18
-0.1%
$8.77
$5.90
$11.08
$317.55M1.53101,608 shs101,743 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Molecular Partners AG stock logo
MOLN
Molecular Partners
+5.57%+2.58%-1.73%-17.60%-41.47%
PetIQ, Inc. stock logo
PETQ
PetIQ
+1.19%+3.09%-8.93%-6.17%+47.40%
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
-0.12%-1.56%-8.60%+0.37%-23.55%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
0.3932 of 5 stars
2.01.00.00.01.90.01.3
PetIQ, Inc. stock logo
PETQ
PetIQ
1.6849 of 5 stars
3.51.00.00.00.01.71.9
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
2.00
Hold$4.5013.07% Upside
PetIQ, Inc. stock logo
PETQ
PetIQ
3.00
Buy$29.0070.19% Upside
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/AN/AN/AN/A

Current Analyst Ratings

Latest PETQ, MOLN, CNCE, and VMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/19/2024
PetIQ, Inc. stock logo
PETQ
PetIQ
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $28.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$32.58M12.32N/AN/A$3.24 per share2.58
Molecular Partners AG stock logo
MOLN
Molecular Partners
$7.84M18.46N/AN/A$5.41 per share0.74
PetIQ, Inc. stock logo
PETQ
PetIQ
$1.10B0.46$2.72 per share6.27$7.58 per share2.25
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
$183.01M1.74$0.83 per share9.82$2.96 per share2.76

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
-$69.04M-$2.12N/AN/AN/A-885.11%-31.10%-27.93%5/10/2024 (Estimated)
PetIQ, Inc. stock logo
PETQ
PetIQ
$2.13M$0.06284.0513.97N/A0.19%11.72%3.10%5/8/2024 (Confirmed)
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
$10.24M$0.2631.46N/A5.60%9.59%7.09%5/7/2024 (Confirmed)

Latest PETQ, MOLN, CNCE, and VMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
PetIQ, Inc. stock logo
PETQ
PetIQ
$0.4180N/A-$0.4180N/AN/AN/A  
5/7/2024N/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/AN/AN/AN/AN/AN/A  
3/14/2024Q4 2023
Molecular Partners AG stock logo
MOLN
Molecular Partners
N/A-$0.68-$0.68-$0.68N/A$1.17 million
3/6/2024Q4 2023
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/A$0.09+$0.09$0.09N/A$50.74 million
2/28/2024Q4 2023
PetIQ, Inc. stock logo
PETQ
PetIQ
-$0.38-$0.16+$0.22$0.28$189.70 million$219.93 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
PetIQ, Inc. stock logo
PETQ
PetIQ
N/AN/AN/AN/AN/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/A
9.03
9.03
Molecular Partners AG stock logo
MOLN
Molecular Partners
N/A
13.35
13.35
PetIQ, Inc. stock logo
PETQ
PetIQ
1.97
2.27
1.43
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
0.05
1.19
1.05

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
70.63%
Molecular Partners AG stock logo
MOLN
Molecular Partners
26.55%
PetIQ, Inc. stock logo
PETQ
PetIQ
94.99%
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
74.24%

Insider Ownership

CompanyInsider Ownership
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
11.33%
Molecular Partners AG stock logo
MOLN
Molecular Partners
5.93%
PetIQ, Inc. stock logo
PETQ
PetIQ
9.62%
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
19.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
6447.94 million42.51 millionOptionable
Molecular Partners AG stock logo
MOLN
Molecular Partners
16736.37 million34.21 millionNot Optionable
PetIQ, Inc. stock logo
PETQ
PetIQ
1,93329.43 million26.60 millionOptionable
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
99638.82 million31.37 millionNot Optionable

PETQ, MOLN, CNCE, and VMD Headlines

SourceHeadline
Viemed Healthcare (VMD) Scheduled to Post Earnings on TuesdayViemed Healthcare (VMD) Scheduled to Post Earnings on Tuesday
marketbeat.com - April 30 at 10:54 AM
Viemed Healthcare Announces Date and Time for Conference CallViemed Healthcare Announces Date and Time for Conference Call
globenewswire.com - April 23 at 9:00 AM
Viemed Healthcare: Long-Term Bull Remains Intact But Patience RequiredViemed Healthcare: Long-Term Bull Remains Intact But Patience Required
seekingalpha.com - April 17 at 8:27 AM
Triasima Portfolio Management inc. Trims Stock Position in Viemed Healthcare, Inc. (NASDAQ:VMD)Triasima Portfolio Management inc. Trims Stock Position in Viemed Healthcare, Inc. (NASDAQ:VMD)
marketbeat.com - April 14 at 11:11 AM
Analysts Offer Insights on Healthcare Companies: Silk Road Medical (SILK) and Viemed Healthcare (VMD)Analysts Offer Insights on Healthcare Companies: Silk Road Medical (SILK) and Viemed Healthcare (VMD)
markets.businessinsider.com - April 3 at 2:01 PM
Viemed gets controlling interest in Alabama HMEViemed gets controlling interest in Alabama HME
hmenews.com - April 2 at 2:00 PM
Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama HealthViemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health
globenewswire.com - April 2 at 9:00 AM
Viemed Healthcare, Inc. (VMD) Q4 2023 Earnings Call TranscriptViemed Healthcare, Inc. (VMD) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 9 at 4:47 PM
VMD stock wins price target raise at BeaconVMD stock wins price target raise at Beacon
cantechletter.com - March 7 at 4:59 PM
Viemed Healthcare Inc (VMD) Reports Record Financial Results for 2023Viemed Healthcare Inc (VMD) Reports Record Financial Results for 2023
finance.yahoo.com - March 7 at 3:41 PM
VMD Stock Earnings: Viemed Healthcare Misses EPS, Beats Revenue for Q4 2023VMD Stock Earnings: Viemed Healthcare Misses EPS, Beats Revenue for Q4 2023
msn.com - March 6 at 11:30 PM
Viemed Healthcare Announces Record 2023 Financial ResultsViemed Healthcare Announces Record 2023 Financial Results
globenewswire.com - March 6 at 5:00 PM
Heres what Wall Street expects from Viemed Healthcares earnings reportHere's what Wall Street expects from Viemed Healthcare's earnings report
markets.businessinsider.com - March 5 at 10:59 AM
Viemed Healthcare Inc.Viemed Healthcare Inc.
wsj.com - February 22 at 9:29 PM
Viemed Healthcare Announces Date and Time for Conference CallViemed Healthcare Announces Date and Time for Conference Call
globenewswire.com - February 20 at 4:30 PM
Investors in Viemed Healthcare (NASDAQ:VMD) have seen decent returns of 83% over the past five yearsInvestors in Viemed Healthcare (NASDAQ:VMD) have seen decent returns of 83% over the past five years
finance.yahoo.com - January 10 at 7:09 AM
Should You Hold Viemed Healthcare (VMD)?Should You Hold Viemed Healthcare (VMD)?
finance.yahoo.com - December 26 at 9:21 AM
Are Investors Undervaluing Viemed Healthcare, Inc. (NASDAQ:VMD) By 46%?Are Investors Undervaluing Viemed Healthcare, Inc. (NASDAQ:VMD) By 46%?
finance.yahoo.com - December 24 at 11:59 AM
Viemed Healthcare Inc Ordinary SharesViemed Healthcare Inc Ordinary Shares
morningstar.com - December 21 at 10:01 AM
Is Viemed Healthcare, Inc. (TSE:VMD) Trading At A 50% Discount?Is Viemed Healthcare, Inc. (TSE:VMD) Trading At A 50% Discount?
finance.yahoo.com - November 18 at 8:51 AM
Viemed Healthcare Inc Ordinary Shares VMDViemed Healthcare Inc Ordinary Shares VMD
morningstar.com - November 11 at 5:04 AM
Viemed Healthcare to Present at Stifel 2023 Healthcare ConferenceViemed Healthcare to Present at Stifel 2023 Healthcare Conference
finance.yahoo.com - November 7 at 9:40 AM
Viemed Healthcare, Inc.: Viemed Healthcare Announces Record Third Quarter 2023 Financial ResultsViemed Healthcare, Inc.: Viemed Healthcare Announces Record Third Quarter 2023 Financial Results
finanznachrichten.de - November 2 at 7:42 AM
Viemed Healthcare Announces Record Third Quarter 2023 Financial ResultsViemed Healthcare Announces Record Third Quarter 2023 Financial Results
finance.yahoo.com - November 1 at 6:12 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Concert Pharmaceuticals logo

Concert Pharmaceuticals

NASDAQ:CNCE
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
Molecular Partners logo

Molecular Partners

NASDAQ:MOLN
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
PetIQ logo

PetIQ

NASDAQ:PETQ
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.
Viemed Healthcare logo

Viemed Healthcare

NASDAQ:VMD
Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.